News
INO
1.180
-2.48%
-0.030
Inovio Pharmaceuticals Inc. Stock Rallies 8.3%, Outperforms Peers
Dow Jones · 4d ago
Inovio Pharmaceuticals Inc. Stock Rallies 5.5%, Outperforms Peers
Dow Jones · 6d ago
Weekly Report: what happened at INO last week (0810-0814)?
Weekly Report · 6d ago
Five Below, Achieve, Tronox, Brightstar, Inovio Trending
TipRanks · 08/15 09:01
Inovio Pharmaceuticals Inc. Stock Advances 21.1%, Outperforms Peers
Dow Jones · 08/14 20:33
Inovio Pharmaceuticals Inc. Stock Advances 16.9%, Outperforms Peers
Dow Jones · 08/13 20:33
INOVIO shares jump 18% after Q2 beat
Seeking Alpha · 08/13 18:59
Inovio Pharma Raised to Buy From Hold by Jefferies
Dow Jones · 08/13 16:52
Inovio Pharma Price Target Raised to $3.00/Share From $1.80 by Jefferies
Dow Jones · 08/13 16:52
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3
Benzinga · 08/13 16:43
Analysts’ Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
TipRanks · 08/13 15:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kura Oncology (KURA) and Inovio Pharmaceuticals (INO)
TipRanks · 08/13 10:40
Inovio Pharmaceuticals Balances Progress And Cash Pressures
TipRanks · 08/13 00:06
Inovio Pharmaceuticals Q2 Earnings Call Highlights
NASDAQ · 08/13 00:03
Inovio Pharmaceuticals GAAP EPS of -$0.07 beats by $0.15
Seeking Alpha · 08/12 20:10
*Inovio Pharma 2Q Loss/Shr 7c >INO
Dow Jones · 08/12 20:05
Inovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate
Benzinga · 08/12 20:04
Inovio: Q2 Earnings Snapshot
Barchart · 08/12 15:10
Here are the major earnings after the close Wednesday
Seeking Alpha · 08/12 14:00
Inovio Pharmaceuticals Q2 2026 Earnings Preview
Seeking Alpha · 08/11 21:30
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.